Inflammatory Bowel Disease Clinic

Who we see:

• Patients with a confirmed diagnosis of Crohn’s disease, ulcerative colitis or IBD undifferentiated.
• Patients with non-specific colitis/enteritis found on colonoscopy that requires further characterisation.
• Patients with suspected IBD, including those with elevated faecal calprotectin or other suggestive features.

Exclusion Criteria: 

• Patients without a confirmed or reasonably suspected diagnosis of IBD.

The process for referring a patient is:

1. GP/referrer to send electronic referral. We are no longer accepting faxed referrals for this clinic.
2. The referral will be checked to ensure it is valid. If not valid then extra information will be sourced from the referrer.
3. If valid, the referral will be triaged by clinic doctor.
4. Appointment made as per doctor’s recommendation.
5. Patient notified by confirmation letter as well as a text/call 1 week prior to appointment.

For instruction on how to send an electronic referral, please click to see our resources here.

A valid referral requires:

1. Written by a medical practitioner in a private practice or an SMO (Senior Medical Officer).
2. Written to a named doctor within the clinic.
3. Signed and dated by referring practitioner and include their Provider Number and place of practice.
4. Include length of referral, unless it is a 12 month referral.
5. Patient to have signed financial consent form.

Please refer to the State-wide Referral Criteria for Gastroenterology for specific criteria for the relevant condition.

Is there a waiting list?
Yes. 

Waiting List Details
All referrals are prioritised and allocated according to criteria. We will endeavour to see all urgent referrals within 1-2 weeks.
 

If you hold a valid Medicare card the visit is Bulk Billed.

If you do not hold a Medicare card a fee will be charged on arrival, please contact the clinic for further information. 

Please let us know if you need an interpreter. 

You can contact us by telephoning the Translating and Interpreting Service (TIS) on 131 450. Tell the operator what language you speak, and then ask the interpreter to set up a telephone conversation between you, an interpreter, and us on 9540 7624.
 

Dr Nikola Mitrev

• Maguire B, Mitrev N, Baraty B, Au M, Sorensen K, Kariyawasam V (2025). Exploring the Perceptions and Practices of Exclusive Enteral Nutrition among Adult Inflammatory Bowel Disease Patients, Gastroenterologists, and Dietitians in Australia. JCCPlus (submitted).
• Mitrev N, Kariyawasam V (2024). Treatment endpoints in ulcerative colitis: does one size fit all? World Journal of Gastrointestinal Pharmacology and Therapeutics. 5;15(2):91591
• Huang TD, Rennie M, Martin A, Nagubandi S, liu S, Ge E, Khehra B, Au M, Sivagnanam S, Kwan V, Rogge C, Mitrev N, Kariyawasam V (2024). Impact of cytomegalovirus on outcomes in acute severe ulcerative colitis: A retrospective observational study. Therapeutic Advances in Chronic Disease 28:15
• YK An, N Lindsay, N Allan, E Khoo, R Fernandes, A Amiss, H Pham, K F Wong, S Y Ooi, L Thin, D Lightowler, S J Connor, AJ Williams, P De Cruz, C Li Wai Suen, V Kariyawasam, N Mitrev, S Ghaly, J M Andrews, B Christensen, M P Sparrow, L S White, R V Bryant, N Ding, R Leong, D Van Langenberg, H Seltenreich, K Subramaniam, G Radford-Smith, J Begun, (2023) Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn’s disease patients: results from the AURORA Study including ANZIBDC Cohort. Journal of Crohn's and Colitis, 17, S1
• Karimi K, Lukin A, Moore AR, Pipicella JL, Kanazaki J, Williams AJ, Ng W, Kariyawasam V, Mitrev N, Pandya K, Connor SJ (2023) Adolescents and young adults communicating with gastroenterologists: variation in inflammatory bowel disease clinical communication. Int J Adolesc Med Health 28;35(4):347-361
• Au M, Low P, Rennie M, Mohseni M, Song Y, Kim N, Baraty B, Mitrev N, He E, Ho V, Leong R, Kariyawasam V (2023) Determining efficacy of dynamic multimedia bowel preparation instructions versus standard instructions on adenoma detection and patient reported measures (DIGICLEAN trial): a study protocol for a multicentre, colonoscopist-blinded, randomised controlled trial. BMJ Open 21;13(7)
• Au M, Mitrev N, Leong RW, Kariyawasam V (2022) Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn's disease: A case report and review of literature. World J Clin Cases 16;10(8):2569-2576.
• Mitrev N, Huang H, Hannah B, Kariyawasam V, (2021). Review of Exclusive Enteral Therapy in adult Crohn’s disease. IBD Journal, BMJ Open Gastroenterol, Sep;8(1)
• Mitrev N, Madiha C (joint first authors), Ahlenstiel G, Kariyawasam V (2021). Depression, anxiety and stress among inflammatory bowel disease patients during the COVID19 pandemic: Australian national survey. BMJ Open Gastroenterology 8(1):e000581
• Mitrev N, Kariyawasam V. (2020). Review of therapeutic drug monitoring of infliximab in spondyloarthritis- Catching up with management concepts from other inflammatory conditions. Br J Clin Pharmacol. 86(2):194-195
• Kariyawasam VC, Mourad FH, Mitrev N, Paramsothy S, Selinger CP, Katelaris PH, Jones B, McDonald C, Barr G, Chapman G, Cowlishaw J, Andrews J, Leong RW (2020). Early Thiopurine Maintenance Is Associated with Reduced Proximal Disease Progression and Colectomy Rate in Ulcerative Colitis. Eur J Gastroenterol Hepatol. 1;33(12):1524-1532.
• Co-author and expert advisory group: Kariyawasam V, Subramaniam K, Shelton E, Mitrev N (2019) A practical guide for using Stelara (ustekinumab) in Crohn’s disease. Janssen.
• Perry J, Chen A, Kariyawasam V, Collins G, Choong C, Teh WL, Mitrev N, Kohler F, Leong RWL.(2018) Medication non-adherence in inflammatory bowel diseases is associated with disability. Intest Res;16(4):571-578.
• Mitrev N, Vande Casteele N, Seow C, Andrews J, Connor S, Moore G, Barclay M, Begun J, Bryant R, Chan W, Corte C, Ghaly S, Lemberg D, Kariyawasam V, Lewindon P, Martin J, Mountifield R, Radford-Smith G, Slobodian P, Sparrow M, Toong C, van Langenberg D, Ward M and Leong RW (2017) Review article: Consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics. 46(11-12).
• Mitrev N, Kariyawasam V, Leong RW (2017). Editorial: Infliximab trough cut-off for perianal Crohn’s disease: another piece of the therapeutic drug monitoring-guided infliximab dosing puzzle. Alimentary Pharmacology and Therapeutics. 45(9); 1279-80.
• Mitrev N, Leong RW (2016) Therapeutic drug monitoring of anti-tumour necrosis factor agents in inflammatory bowel disease, Expert Opinion on Drug Safety. 16(3); 303-317.
• Mitrev N, Alswaifi A, Leong RW (2016) Chemoprophylaxis in Inflammatory Bowel Disease, In: Therapeutic Targets for Inflammation and Cancer: Novel Therapies for the Digestive Tract. World Scientific, Singapore (book chapter)
• Leong RW, Mitrev N, Ko Y (2016). Hygiene hypothesis: Is the evidence the same all over the world? Digestive Diseases. 34(1-2); 35-42.

Dr Nan (Betty) Wu

• Wu, N., Mah, C., Koentgen, S et al. Proceedings of the Nutrition Society 2021. Conference on ‘Gut microbiome and health’ Symposium three: Pathogens × gut microbiota interactions: Inflammatory bowel disease and the gut microbiota. Published by Cambridge University Press on behalf of The Nutrition Society
• Williams A*, Paramsothy R*, Wu N*, et al. Australia IBD Microbiome (AIM) Study: protocol for a multicentre longitudinal prospective cohort study BMJ Open 2021;11:e042493. doi: 10.1136/bmjopen-2020-042493
• denotes equal contribution
• Wu, B.N., Petito, V., Scaldaferri, F,. and Hold, G. Microbiota and IBD. Microbiota in Health and Disease. 2019; 1: e199
• Wu, N and Freiman, J.S. Caecal Ulceration in Asymptomatic Man. Gut. 2017; 66: 886
• Wu, B.N. and Yang, J.L. Nanoparticle-Based Chemotherapies on the Market. World Journal of Cancer Research. 2013; 1 (2) 92-107
• Wu, B.N. and O’Sullivan, A.J. Sex Differences in Energy Metabolism Need to Be Considered with Lifestyle Modifications in Humans. Journal of Nutrition and Metabolism. 2011; 2011:391809.
• RD, Little; TC, Jayawardana; F, Zhang; Y, Houshyar; S, Koentgen; N, Wu; A, Ellepola; P, Tavakoli; et al. On behalf of The AIM Study consortium. Gut microbiota are more strongly associated with impairments in health-related quality of life than disease activity in inflammatory bowel disease. The American Journal of Gastroenterology. September 29, 2025. | DOI: 10.14309/ajg.0000000000003773
• Cosier D, Lambert K, Charlton K, Batterham M, Little RD, Wu N, Tavakoli P, Ghaly S, Pipicella JL, Connor S, et al. Dietary Patterns and Fibre Intake Are Associated with Disease Activity in Australian Adults with Inflammatory Bowel Disease: An Exploratory Dietary Pattern Analysis. Nutrients. 2024; 16(24):4349.
• O’Donnell, M., Teasdale, S., Chua, XY., Hardman, J., Wu, N., et al. The role of the microbiome in the metabolic health of people with schizophrenia and related psychosis: cross-sectional and pre-post lifestyle intervention analyses. Pathogens. 2022, 11, 1279.
• Ferrie S, Webster A, Wu BN, Tan C and Carey S. (2020) Gastrointestinal Surgery and the Gut Microbiome: A Systematic Literature Review. European Journal of Clinical Nutrition.